Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23603002 | 0.93 | — | — | |
| SCHEMBL15166346 | 0.93 | — | — | |
| SCHEMBL4838694 | 0.93 | — | — | |
| SCHEMBL15818137 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL15157640 | 0.91 | SLC6A2 (0.36) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL15157638 | 0.91 | SLC6A2 (0.36) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL15157637 | 0.91 | SLC6A2 (0.36) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| Tert-Butyl Formate SCHEMBL27801680 | 0.82 | TDP1 (0.38) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL271159 | 0.81 | SLC6A3 (0.42) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL3601118 | 0.80 | SLC6A3 (0.41) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130224195-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | COSTALES ABRAN (US) | 2013-08-29 | — | — | US | disclosed |
| US-8415382-B2 | Substituted benzazoles and methods of their use as inhibitors of RAF Kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| EP-1682126-B1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090035309-A1 | Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase | NOVARTIS AG | 2009-02-05 | — | — | US | disclosed |
| US-7423150-B2 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2008-09-09 | — | — | US | disclosed |
| US-20050192287-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | CHIRON CORPORATION (US) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035309-A1 | Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase | BRAF, RAF1, ARAF | SLC6A3 3355/4885SLC6A2 4667/4885SLC6A4 4364/4885 |
| US-20130224195-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | BRAF, RAF1, ARAF | SLC6A3 3355/4885SLC6A2 4667/4885SLC6A4 4364/4885 |
| US-20050192287-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | SLC6A3 3355/4885SLC6A2 4667/4885SLC6A4 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.